NanoString Technologies (NanoString Technologies) Cash-to-Debt : 0.39 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NanoString Technologies's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.39.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, NanoString Technologies couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for NanoString Technologies's Cash-to-Debt or its related term are showing as below:

NSTGQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39 Med: 1.39 Max: 4.96
Current: 0.39

During the past 13 years, NanoString Technologies's highest Cash to Debt Ratio was 4.96. The lowest was 0.39. And the median was 1.39.

NSTGQ's Cash-to-Debt is ranked worse than
77.79% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs NSTGQ: 0.39

NanoString Technologies Cash-to-Debt Historical Data

The historical data trend for NanoString Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NanoString Technologies Cash-to-Debt Chart

NanoString Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

1.61

1.39

2.18

1.39

0.79

NanoString Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															0.92	0.79	0.62	0.47	0.39

Competitive Comparison of NanoString Technologies's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, NanoString Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NanoString Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoString Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NanoString Technologies's Cash-to-Debt falls into.

NanoString Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NanoString Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	196.532	/	(5.518	+	244.984)
	=	0.78

NanoString Technologies's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	97.101	/	(5.578	+	242.124)
	=	0.39

NanoString Technologies (OTCPK:NSTGQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NanoString Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoString Technologies (NanoString Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0F1:Germany

Address

530 Fairview Avenue North, Seattle, WA, USA, 98109

Website

https://www.nanostring.com

NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.

Executives

Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey	officer: Chief Financial Officer	1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray	director, officer: President and CEO	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr	director, 10 percent owner	11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem	officer: SVP, Research & Development	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace	officer: Chief Commercial Officer	C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown	officer: SVP, Sales & Marketing	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Janet George	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109